Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXA14007 + azithromycin
- Development stage
- Preclinical
- Lead developer
- TAXIS Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TXA14007 + azithromycin is a small molecule combination therapy under development by TAXIS Pharmaceuticals. The product combines TXA14007, a novel bacterial efflux pump inhibitor, with the macrolide antibiotic azithromycin. This combination is designed to address multidrug-resistant Gram-negative bacterial infections, including those caused by *Escherichia coli*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*. By inhibiting the efflux pumps that bacteria use to expel toxic substances, TXA14007 prevents the extrusion of azithromycin from the bacterial cell, thereby restoring the antibiotic's efficacy and enhancing its antibacterial activity against resistant strains. The program is currently in the lead optimization stage of preclinical development.
- Other names
- TXA14007/azithromycin
02
Targets
BEP (Bacterial multidrug efflux pump)Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on TXA14007 + azithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXA14007 + azithromycin.